Cracking Complexity: Learnings from 70+ Bispecific Antibody Programs

In this webinar, Lonza experts share insights from 70+ bispecific programs, revealing the most common early‑stage risks across analytical development, downstream purification, and drug product formulation. You’ll learn where challenges typically emerge before IND, how early decisions shape CMC readiness, and when to rely on platform approaches versus molecule‑specific strategies to avoid costly delays.

Key Learning Objectives:
– Identify where development risks matter most before IND and what early stage challenges bispecific antibody programs most commonly run into
– Understand how early analytical, downstream, and drug product formulation decisions can either accelerate progress or create downstream CMC and IND readiness challenges
– Learn how Lonza balances speed and risk by knowing when platform approaches are sufficient and when molecule specific strategies are needed to avoid costly surprises